PDE12

PDE12 is a mitochondria-localized poly(A)-specific exoribonuclease that maintains mitochondrial RNA integrity and also functions as a negative regulator of the OAS/RNase L innate immune pathway. Within mitochondria, PDE12 removes spurious poly(A) extensions from mitochondrial mRNAs and non-coding RNAs; excess PDE12 severely inhibits mitochondrial protein synthesis and disrupts oxidative phosphorylation, while loss-of-function leads to accumulation of aberrantly polyadenylated mitochondrial RNAs, respiratory chain deficiency, and neonatal disease in humans (PMID:21666256, PMID:39567835, PMID:38325798). PDE12 also degrades 2',5'-oligoadenylate (2-5A), and PDE12-null cells exhibit elevated 2-5A levels and enhanced resistance to encephalomyocarditis virus, rhinovirus, and RSV (PMID:26055709). Transcription of PDE12 is directly upregulated by EGR1 binding to its promoter (PMID:42000021).

1. 2011 High

   Establishing that PDE12 is a mitochondrial poly(A)-specific exoribonuclease answered the fundamental question of what enzyme trims poly(A) tails from mitochondrial mRNAs and revealed that its overexpression inhibits mitochondrial translation and respiration.

   Evidence In vitro deadenylation assays, mitochondrial fractionation, translation assays, and respiratory function measurements in cultured cells

   PMID:21666256

   Open questions at the time

   • No identification of how PDE12 activity is regulated in vivo
   • Substrate specificity across all mitochondrial RNA species not fully mapped
   • No structural information on enzyme–substrate interaction
2. 2015 High

   Demonstrating that PDE12 degrades 2-5A and that its loss enhances antiviral resistance established a second, cytosolic function as a negative regulator of the OAS/RNase L innate immune pathway, broadening PDE12's role beyond mitochondrial RNA metabolism.

   Evidence TALEN-mediated PDE12 knockout cells, 2-5A quantification, viral resistance assays against EMCV/rhinovirus/RSV, crystal structure of PDE12 with an inhibitor

   PMID:26055709

   Open questions at the time

   • How PDE12 partitions between mitochondrial and cytosolic/2-5A degradation pools is unknown
   • Relative physiological importance of the 2-5A degradation versus mitochondrial poly(A) trimming functions not resolved
   • No in vivo animal model validation of antiviral phenotype
3. 2024 High

   Discovery that bi-allelic PDE12 mutations cause neonatal disease with aberrantly polyadenylated mitochondrial RNAs and COX deficiency established PDE12 as essential for human mitochondrial RNA quality control and linked it to a Mendelian respiratory chain disorder.

   Evidence Whole exome sequencing in three unrelated families, MPAT-Seq of patient fibroblasts, mitochondrial respiratory chain enzymology

   PMID:39567835

   Open questions at the time

   • Precise mechanism by which aberrant polyadenylation of non-coding mt-RNAs disrupts OXPHOS not delineated
   • No rescue experiment with wild-type PDE12 in patient cells reported
   • Genotype–phenotype spectrum across different PDE12 variants remains limited to a few families
4. 2024 Medium

   Showing that PDE12 overexpression disrupts OXPHOS complexes, membrane potential, and epithelial tight junctions — and that knockdown rescues these phenotypes — connected excessive PDE12 activity to mitochondrial ROS generation and epithelial-mesenchymal transition.

   Evidence PDE12 overexpression and siRNA knockdown in HOK cells with OXPHOS complex quantification, membrane potential assays, mtROS measurement, and transepithelial electrical resistance

   PMID:38325798

   Open questions at the time

   • Single cell type (oral keratinocyte); generalizability to other epithelia not tested
   • Whether EMT is a direct consequence of PDE12-driven mitochondrial dysfunction or a secondary effect is unclear
   • No identification of specific mt-RNA substrates mediating the OXPHOS disruption upon overexpression
5. 2026 Medium

   Identification of EGR1 as a direct transcriptional activator of PDE12 answered how PDE12 expression is upregulated, placing it downstream of a stress-responsive transcription factor.

   Evidence EMSA and ChIP demonstrating EGR1 binding to PDE12 promoter; EGR1 silencing rescues PDE12-overexpression-driven mitochondrial dysfunction

   PMID:42000021

   Open questions at the time

   • Whether EGR1 is the sole or primary transcriptional regulator of PDE12 is not established
   • Physiological signals upstream of EGR1 that drive PDE12 upregulation beyond arecoline exposure are unknown
   • Single lab finding; independent replication in other systems not yet reported

• How PDE12 partitions between its mitochondrial poly(A) trimming and cytosolic 2-5A degradation functions, and what governs substrate selection among different mitochondrial RNA species, remain unresolved.
• No dual-localization trafficking mechanism elucidated
• No structural model of PDE12 engaged with a mitochondrial RNA substrate
• Relative contribution of the two functions to human disease phenotypes unknown